Assuntos
Anafilaxia/etiologia , Anisaquíase/complicações , Adulto , Anafilaxia/diagnóstico , Anafilaxia/tratamento farmacológico , Animais , Anisaquíase/diagnóstico , Anisaquíase/tratamento farmacológico , Anisakis/efeitos dos fármacos , Anisakis/isolamento & purificação , Anti-Helmínticos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Humanos , Masculino , Alimentos Marinhos/efeitos adversos , Alimentos Marinhos/parasitologia , Resultado do TratamentoAssuntos
Encefalopatias/induzido quimicamente , Encefalopatias/microbiologia , Neuroaspergilose/induzido quimicamente , Infecções Oportunistas/induzido quimicamente , Pirazóis/efeitos adversos , Pirimidinas/efeitos adversos , Adenina/análogos & derivados , Idoso , Humanos , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Masculino , Piperidinas , Pirazóis/uso terapêutico , Pirimidinas/uso terapêuticoRESUMO
Pneumocystis jiroveci (formerly P. carinii) is an opportunistic fungus responsible for pneumonia in immunocompromised patients. Pneumocystosis in non-HIV-infected patients differs from AIDS-associated pneumocystosis in mostly two aspects: diagnosis is more difficult, and prognosis is worse. Hence, efforts should be made to target immunocompromised patients at higher risk of pneumocystosis, so that they are prescribed long-term, low-dose, trimethoprime-sulfamethoxazole, highly effective for pneumocystosis prophylaxis. Patients at highest risk include those with medium and small vessels vasculitis, lymphoproliferative B disorders (chronic or acute lymphocytic leukaemia, non-Hodgkin lymphoma), and solid cancer on long-term corticosteroids. Conversely, widespread use of prophylaxis in all patients carrier of inflammatory diseases on long-term corticosteroids is not warranted. The management of pneumocystosis in non-AIDS immunocompromised patients follows the rules established for AIDS patients. The diagnosis relies on the detection of P. jiroveci cyst on respiratory samples, while PCR does not reliably discriminate infection from colonization, in 2015. High-doses trimethoprim-sulfamethoxazole is, by far, the treatment of choice. The benefit of adjuvant corticosteroid therapy for hypoxic patients, well documented in AIDS patients, has a much lower level of evidence in non-HIV-infected patients, most of them being already on corticosteroid by the time of pneumocystosis diagnosis anyway. However, based on its striking impact on morbi-mortality in AIDS patients, adjuvant corticosteroid is recommended in hypoxic, non-HIV-infected patients with pneumocystosis by many experts and scientific societies.
Assuntos
Hospedeiro Imunocomprometido , Pneumonia por Pneumocystis/terapia , Corticosteroides/uso terapêutico , Antibioticoprofilaxia/métodos , Antibioticoprofilaxia/estatística & dados numéricos , Humanos , Pneumocystis carinii , Pneumonia por Pneumocystis/epidemiologia , Pneumonia por Pneumocystis/imunologia , Pneumonia por Pneumocystis/prevenção & controleRESUMO
The sources of exposure during diseases due to Aspergillus fungi in cystic fibrosis patients are still poorly explored. We assessed home fungal exposure in patients suffering from cystic fibrosis and analysed its impact on the presence of Aspergillus biological markers, the colonisation of airways, as well as the sensitization and Aspergillus serology. Between March 2012 and August 2012, 34 patients benefited from a visit performed by a home environment medical adviser including sampling for mycological analysis. The number of colonies of Aspergillus was not significantly different in the various sampling sites (P=0.251), but the number of non-Aspergillus colonies was much higher in the kitchen (P=0.0045). Subsequently, home fungal exposure was compared between the groups "absence of Aspergillus-related markers" and "presence of Aspergillus-related markers". Home exposure to Aspergillus (P=0.453) and non-Aspergillus (P=0.972) flora was not significant between the 2 groups. Within this series of 34 patients that should be expanded, we note an absence of clear relationship between home exposure and the Aspergillus-linked markers in patients suffering from cystic fibrosis. This result should be taken into account regarding too restrictive hygiene advices provided to families, given the fact that fungal exposure can also results from activities performed away from home.